Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Rakesh Jain
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
XTuit Pharmaceticals
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Dr. Jain is a co-founder and Board Member of XTuit Pharmaceuticals, a company developing novel microenvironment-activated therapeutics. In addition, Dr. Jain is an inventor of technology licensed to the company through the hospital. This research project is studying whether targeting the physical microenvironment can enhance the efficacy of systemic treatment of pancreatic ductal adenocarcinoma in obese patients and improve the prognosis. The results of the research could potentially enhance the value of the technology licensed to XTuit. The institution determined that, given the magnitude of the financial interest in addition to the close connection between the aims of the company’s interests and the aims of the research, Dr. Jain’s financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Reengineering obesity-induced abnormal microenvironment to improve PDAC treatment
PROJECT NARRATIVE Obesity associates with worse prognosis of pancreatic ductal adenocarcinoma (PDAC), but the mechanisms remain poorly understood. Obesity promotes inflammation and fibrosis in the pancreas, but whether this extends to the PDAC microenvironment to alter the biomechanical properties of the tumor and reduce drug effectiveness is unknown. This Bioengineering Research Grant Project will determine the effect of obesity on PDAC desmoplasia and mechanical properties, and develop and test new therapeutic approaches that reverse the abnormal PDAC biomechanics in obesity. The overall goal is to determine if targeting the physical microenvironment can enhance the efficacy of systemic treatment of PDAC in obese patients and improve the prognosis.
Filed on June 30, 2017.
Tell us what you know about Rakesh Jain's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Rakesh Jain filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Rakesh Jain | Massachusetts General Hospital | Conflict of Interest | XTuit Pharmaceticals | $20,000 - $39,999 |
| Rakesh Jain | Massachusetts General Hospital | Conflict of Interest | Xtuit Pharmaceuticals, Inc. | $5,000 - $9,999 |
| Rakesh Jain | Massachusetts General Hospital | Conflict of Interest | XTuit Pharmaceticals | Value cannot be readily determined |
| Rakesh Jain | Massachusetts General Hospital | Conflict of Interest | XTuit Pharmaceticals | Value cannot be readily determined |
| Rakesh Jain | Massachusetts General Hospital | Conflict of Interest | Xtuit Pharmaceuticals, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.